The partial hold comes after Nurix told the agency of its plan to “transition to an improved manufacturing process,” the drugmaker said in a Nov. 1 news release.
The study is testing Nurix’s drug NX-2127 and involves 160 adult participants with relapsed or refractory B-cell malignancies, according to clinicaltrials.gov. Patients already receiving treatment will continue their regimens, but new enrollment is currently paused with the clinical hold.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.